AU2019417161B2 - Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease - Google Patents
Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease Download PDFInfo
- Publication number
- AU2019417161B2 AU2019417161B2 AU2019417161A AU2019417161A AU2019417161B2 AU 2019417161 B2 AU2019417161 B2 AU 2019417161B2 AU 2019417161 A AU2019417161 A AU 2019417161A AU 2019417161 A AU2019417161 A AU 2019417161A AU 2019417161 B2 AU2019417161 B2 AU 2019417161B2
- Authority
- AU
- Australia
- Prior art keywords
- betamethasone
- pharmaceutical composition
- sodium
- disease
- ocular surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785312P | 2018-12-27 | 2018-12-27 | |
| US62/785,312 | 2018-12-27 | ||
| PCT/US2019/064371 WO2020139525A1 (en) | 2018-12-27 | 2019-12-04 | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019417161A1 AU2019417161A1 (en) | 2021-07-15 |
| AU2019417161B2 true AU2019417161B2 (en) | 2023-06-15 |
Family
ID=71127864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019417161A Ceased AU2019417161B2 (en) | 2018-12-27 | 2019-12-04 | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12070442B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3902525A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022516099A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210141448A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113473970A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019417161B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021012492A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3124945A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL284344A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021007709A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202106967QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020139525A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3548091T (pt) | 2016-11-29 | 2022-01-21 | Oculis SA | Preparação de complexos sólidos de ciclodextrina para administração oftálmica de ingrediente farmacêutico ativo |
| US11766421B2 (en) * | 2017-09-25 | 2023-09-26 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| WO2022076398A1 (en) * | 2020-10-07 | 2022-04-14 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| JP2022516099A (ja) | 2018-12-27 | 2022-02-24 | サーフィス オフサルミクス,インコーポレイテッド | 眼科用医薬組成物及び癌表面疾患の処置方法 |
| WO2021001366A1 (en) | 2019-07-01 | 2021-01-07 | Oculis SA | Method for stabilizing the ph of an aqueous composition comprising a drug |
| CN117979951A (zh) | 2021-05-10 | 2024-05-03 | 瑟菲斯眼科股份有限公司 | 一种用于缓解眼部疼痛的硫酸软骨素的用途 |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| WO2023141334A2 (en) * | 2022-01-24 | 2023-07-27 | Surface Ophthalmics, Inc. | Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders |
| IL320428A (en) | 2022-11-04 | 2025-06-01 | Qlaris Bio Inc | Topical ophthalmic administration of cromolyns |
| EP4616843A1 (en) * | 2024-03-13 | 2025-09-17 | Iakov Mirkin | Pharmaceutical composition for use in the treatment of ulcerative colitis and in the treatment of interstitial cystitis/bladder pain syndrome |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010041671A1 (en) * | 2000-04-07 | 2001-11-15 | Napoli Guido Di | Ophthalmic formulations |
| US20050063996A1 (en) * | 2003-09-19 | 2005-03-24 | Gholam Peyman | Ocular solutions |
| WO2006073786A2 (en) * | 2004-12-30 | 2006-07-13 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| US9789080B2 (en) * | 2015-09-04 | 2017-10-17 | Insite Vision Incorporated | Ophthalmic formulations of mycophenolic acid |
| US10058616B2 (en) * | 2012-02-10 | 2018-08-28 | Tlc Biopharmaceuticals, Inc. | Pharmaceutical compositions to reduce complications of ocular steroid |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2503563A1 (fr) | 1981-04-09 | 1982-10-15 | Pos Lab | Composition pour collyre a base de sulfate de chondroitine a |
| US4863907A (en) | 1984-06-29 | 1989-09-05 | Seikagaku Kogyo Co., Ltd. | Crosslinked glycosaminoglycans and their use |
| US4696917A (en) | 1985-08-01 | 1987-09-29 | Lindstrom Richard L | Irrigation solution |
| CA2041828A1 (en) | 1990-03-05 | 1992-11-04 | Richard L. Lindstrom | Viscoelastic solution |
| ES2154262T3 (es) | 1991-04-26 | 2001-04-01 | Fujisawa Pharmaceutical Co | Uso de compuestos macrolidos para enfermedades oculares. |
| US5518732A (en) | 1995-02-14 | 1996-05-21 | Chiron Vision, Inc. | Bio-erodible ophthalmic shield |
| US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| CZ20013769A3 (cs) | 1999-04-30 | 2002-03-13 | Sucampo Ag | Činidlo pro léčbu suchého oka |
| US6489335B2 (en) | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| CN1127955C (zh) | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | 一种眼前段及眼表免疫相关性疾病治疗药物 |
| DE10045343B4 (de) | 2000-09-14 | 2005-05-12 | Neuhann, Tobias, Dr.med. | Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels |
| US6878694B2 (en) | 2000-12-20 | 2005-04-12 | Alcon, Inc. | Ophthalmic irrigating solution adapted for use in lasik surgery |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| EP1706095B1 (en) | 2004-01-20 | 2008-12-24 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| GB0404693D0 (en) | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
| US7820639B2 (en) | 2004-10-01 | 2010-10-26 | Lindstrom Richard L | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same |
| CA2584427A1 (en) | 2004-11-23 | 2006-06-01 | Alcon, Inc. | Triple natural polymer viscoelastic composition |
| US20070082841A1 (en) * | 2005-09-27 | 2007-04-12 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| DE102005055275A1 (de) | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung |
| KR101478164B1 (ko) | 2006-02-09 | 2014-12-31 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| US20070259021A1 (en) | 2006-05-01 | 2007-11-08 | Friedlaender Mitchell H | Compositions, Methods, and Kits for Treating Dry Eye |
| US20080242646A1 (en) | 2007-03-26 | 2008-10-02 | Lessem Jan N | Split dose corticosteroid therapy |
| JP5202986B2 (ja) | 2007-09-14 | 2013-06-05 | ロート製薬株式会社 | コンタクトレンズ装着液 |
| US9034843B2 (en) | 2007-09-14 | 2015-05-19 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic composition |
| EP2229174A1 (en) | 2007-12-04 | 2010-09-22 | Novagali Pharma S.A. | Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders |
| JP2011527339A (ja) * | 2008-07-09 | 2011-10-27 | アスプレバ インターナショナル リミテッド | 眼障害を処置するためのミコフェノール酸ナトリウムのpH特異的な溶液 |
| US10980818B2 (en) | 2009-03-06 | 2021-04-20 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| US10201548B2 (en) | 2009-03-06 | 2019-02-12 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| JP5595206B2 (ja) | 2009-09-30 | 2014-09-24 | ロート製薬株式会社 | 眼科用液体組成物 |
| EP2308468A1 (en) | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| WO2011059819A2 (en) | 2009-10-29 | 2011-05-19 | Colorado State University Research Foundation | Polymeric materials including a glycosaminoglycan networked with a polyolefin-containing polymer |
| FR2962044B1 (fr) | 2010-04-21 | 2013-02-22 | Horus Pharma | Emulsion lacrymimetique |
| US9233123B1 (en) | 2010-12-07 | 2016-01-12 | Richard L. Lindstrom | Use of ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan |
| EP2695621B1 (en) | 2011-04-08 | 2020-08-12 | Nanotheta Co, Ltd. | Pharmaceutical preparation |
| WO2013126602A1 (en) | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| ITPD20120098A1 (it) | 2012-03-30 | 2013-10-01 | Fidia Farmaceutici | "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico" |
| ITMI20120896A1 (it) | 2012-05-23 | 2013-11-24 | Bongulielmi Reto | Condroitina per uso in medicina |
| JP6452283B2 (ja) | 2012-11-06 | 2019-01-16 | ロート製薬株式会社 | 眼の異物感改善剤 |
| AU2013342275B2 (en) * | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| JP6403062B2 (ja) | 2012-12-21 | 2018-10-10 | 国立大学法人徳島大学 | 組織修復活性組成物及びその利用 |
| US10098962B2 (en) | 2013-07-10 | 2018-10-16 | Seikagaku Corporation | Glycosaminoglycan derivative and method for producing same |
| US20150100348A1 (en) | 2013-10-08 | 2015-04-09 | Ims Health Incorporated | Secure Method for Health Record Transmission to Emergency Service Personnel |
| EP2979689A1 (en) | 2014-07-29 | 2016-02-03 | Sygene Technologies | Composition for an eye drop and delivery system therefor |
| JP2016050181A (ja) * | 2014-08-29 | 2016-04-11 | 大日本住友製薬株式会社 | 血管炎治療剤 |
| WO2016114397A1 (ja) | 2015-01-16 | 2016-07-21 | 生化学工業株式会社 | コンドロイチン硫酸架橋体、並びにこれを含有する組成物、及び眼疾患処置剤 |
| TWI773641B (zh) | 2015-05-08 | 2022-08-11 | 日商活效製藥股份有限公司 | 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑 |
| JP6847866B2 (ja) | 2016-01-29 | 2021-03-24 | 生化学工業株式会社 | コンドロイチン硫酸及びヒアルロン酸を含有する安定化された水性組成物 |
| JP7288289B2 (ja) | 2016-11-11 | 2023-06-07 | ロート製薬株式会社 | 水性眼科組成物 |
| AU2017372976B2 (en) | 2016-12-11 | 2023-12-07 | Seanergy Dermatology Ltd. | Compositions comprising sulfated polysaccharides |
| WO2018114557A1 (en) | 2016-12-22 | 2018-06-28 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| US20190008920A1 (en) | 2017-05-19 | 2019-01-10 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| CN110996904A (zh) * | 2017-05-19 | 2020-04-10 | 奥古根有限公司 | 眼用组合物及使用方法 |
| US11766421B2 (en) | 2017-09-25 | 2023-09-26 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| US20220143075A1 (en) | 2017-09-25 | 2022-05-12 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| US20230277557A1 (en) | 2017-09-25 | 2023-09-07 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| JP7104553B2 (ja) | 2018-03-30 | 2022-07-21 | ロート製薬株式会社 | 眼科組成物 |
| JP7417365B2 (ja) | 2018-05-09 | 2024-01-18 | ロート製薬株式会社 | 水性眼科組成物 |
| TWI894824B (zh) | 2018-05-09 | 2025-08-21 | 日商樂敦製藥股份有限公司 | 眼科組成物 |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| JP2022516099A (ja) | 2018-12-27 | 2022-02-24 | サーフィス オフサルミクス,インコーポレイテッド | 眼科用医薬組成物及び癌表面疾患の処置方法 |
| JP6866412B2 (ja) | 2019-02-28 | 2021-04-28 | 株式会社伊勢半 | 油中水型乳化化粧料 |
| JP7758466B2 (ja) | 2019-11-07 | 2025-10-22 | ロート製薬株式会社 | 眼科組成物 |
| WO2021162529A1 (ko) | 2020-02-14 | 2021-08-19 | 연세대학교 산학협력단 | 페놀 유도체가 수식된 콘드로이틴 설페이트 하이드로젤 및 이의 용도 |
| JP2022157707A (ja) | 2021-03-31 | 2022-10-14 | ロート製薬株式会社 | 眼科組成物 |
| US12359542B2 (en) | 2021-05-12 | 2025-07-15 | Schlumberger Technology Corporation | Autonomous inflow control device system and method |
| WO2023141334A2 (en) | 2022-01-24 | 2023-07-27 | Surface Ophthalmics, Inc. | Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders |
-
2019
- 2019-12-04 JP JP2021537848A patent/JP2022516099A/ja active Pending
- 2019-12-04 MX MX2021007709A patent/MX2021007709A/es unknown
- 2019-12-04 US US17/418,813 patent/US12070442B2/en active Active
- 2019-12-04 EP EP19902055.3A patent/EP3902525A4/en active Pending
- 2019-12-04 BR BR112021012492-6A patent/BR112021012492A2/pt not_active Application Discontinuation
- 2019-12-04 AU AU2019417161A patent/AU2019417161B2/en not_active Ceased
- 2019-12-04 CN CN201980092852.9A patent/CN113473970A/zh active Pending
- 2019-12-04 SG SG11202106967QA patent/SG11202106967QA/en unknown
- 2019-12-04 WO PCT/US2019/064371 patent/WO2020139525A1/en not_active Ceased
- 2019-12-04 CA CA3124945A patent/CA3124945A1/en active Pending
- 2019-12-04 KR KR1020217023758A patent/KR20210141448A/ko not_active Withdrawn
-
2021
- 2021-06-24 IL IL284344A patent/IL284344A/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010041671A1 (en) * | 2000-04-07 | 2001-11-15 | Napoli Guido Di | Ophthalmic formulations |
| US20050063996A1 (en) * | 2003-09-19 | 2005-03-24 | Gholam Peyman | Ocular solutions |
| WO2006073786A2 (en) * | 2004-12-30 | 2006-07-13 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| US10058616B2 (en) * | 2012-02-10 | 2018-08-28 | Tlc Biopharmaceuticals, Inc. | Pharmaceutical compositions to reduce complications of ocular steroid |
| US9789080B2 (en) * | 2015-09-04 | 2017-10-17 | Insite Vision Incorporated | Ophthalmic formulations of mycophenolic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210141448A (ko) | 2021-11-23 |
| BR112021012492A2 (pt) | 2021-09-08 |
| CN113473970A (zh) | 2021-10-01 |
| WO2020139525A1 (en) | 2020-07-02 |
| EP3902525A1 (en) | 2021-11-03 |
| MX2021007709A (es) | 2021-12-15 |
| AU2019417161A1 (en) | 2021-07-15 |
| US20220071945A1 (en) | 2022-03-10 |
| JP2022516099A (ja) | 2022-02-24 |
| SG11202106967QA (en) | 2021-07-29 |
| IL284344A (en) | 2021-08-31 |
| EP3902525A4 (en) | 2022-09-28 |
| CA3124945A1 (en) | 2020-07-02 |
| US12070442B2 (en) | 2024-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12070442B2 (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | |
| US11766421B2 (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | |
| US10561607B2 (en) | Pharmaceutical compositions comprising gels and methods for fabricating thereof | |
| US20230277557A1 (en) | Pharmaceutical kits and their use for treating dry eye disease | |
| TWI544934B (zh) | 含有氟喹諾酮抗生素藥物之經改良藥學組成物 | |
| US20220143075A1 (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | |
| US20110144027A1 (en) | Pharmaceutical compositions for promoting wound healing | |
| US20170112936A1 (en) | Pharmaceutical compositions comprising gels and methods for fabricating thereof | |
| JP2025513090A (ja) | 眼疾患の治療のためのミコフェノール酸及び/又はベタメタゾンの医薬組成物 | |
| AU2025203019A1 (en) | Ophthalmic Compositions Containing A Nitric Oxide Releasing Prostamide | |
| CA3250770A1 (en) | MULTIDOSE OPHTHALMIC COMPOSITIONS | |
| WO2022076398A1 (en) | Pharmaceutical kits and their use for treating dry eye disease | |
| WO2022240598A1 (en) | Use of chondroitin sulfate for relieving ocular pain | |
| US20200155450A1 (en) | Pharmaceutical compositions comprising gels and methods for fabricating thereof | |
| TW202329958A (zh) | 西維美林水溶液組合物和使用方法 | |
| US8679511B2 (en) | In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts | |
| US20230158045A1 (en) | Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders | |
| RU2781022C2 (ru) | Офтальмологические композиции, содержащие простамид, высвобождающий окись азота | |
| HK40018890B (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide | |
| HK40018890A (en) | Ophthalmic compositions containing a nitric oxide releasing prostamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |